FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease

SILVER SPRING, Md., March 14, 2024 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with…